Important Strategies to Stop COVID-19: From Traditional Medicine to the Modern Vaccines

Habibi Rezaei, Mehran; Yousefi, Reza

Important Strategies to Stop COVID-19: From Traditional Medicine to the Modern Vaccines

Document Type : Promotion Article

Authors

Mehran Habibi rezaei ¹
Reza Yousefi ²

¹ School of Biology, College of Science, University of Tehran, Iran.

² Faculty of Science, Shiraz University, Shiraz, Iran

Abstract

Due to the ease of transportation in the modern world and the lack of familiarity with the human immune system, the new coronavirus quickly crossed the borders of the country after it first appeared in China late 2019. Through the rapid spreading to more than 171 countries in the world, it now becomes the biggest challenge after World War II. Tens of thousands of people, including many medical staff, have been infected and thousands have died, but effective and definitive treatment has not yet been reported. On the other hand, concerted global efforts to halt epidemi of the killer virus have been started few months ago and continue by now. To this end, many governments, organizations, institutions and charities around the world have begun to provide serious support to universities and pharmaceutical companies. Because of this monetary support, dozens of vaccines and antibodies have been developed that are in clinical trial stages and are likely to be released soon. In addition to the design of new vaccines and antibodies, other drugs, particularly those used for viral infections, and traditional herbal remedies have also been given the opportunity to re-emerge. Also, many projects have used the potential capacity of stem cells to control this infectious disease. The construction of new and innovative drugs is also on the agenda of scientists. Considering the genetic information of spike protein, several DNA, RNA and protein vaccines have been developed, so far. The spike protein is also a good target for many of the antibodies that are being made, which will neutralize the virus by binding to this protein that protruded from the viral surface. Some pharmacological antibodies, such as Kevzara, Leronlimab, and Actemra, which have previously been used to treat other conditions, have recently been suggested to reduce pulmonary inflammation and facilitate the pulmonary ventilation in the patients. Also, the antiviral medicines Lopinavir, Ritonavir, Remdesivir, Galidesivir, Oseltamivir, Darunavir, Triazavirin, and the antibiotic Brilacidin, and several other important drugs, have attracted the attention of physicians and researchers to combat the disease. The plant-based compounds such as the anti-malarial drug chloroquine, glycyrrhizinate diammonium from licorice root juice, and the Flavonoid baicalin have also shown positive results in controlling this viral disease.This article describes the pioneering plans in the field of trial drugs in various stages of clinical trials for the treatment of covid-19. Throughout the thousands of years of history, mankind has repeatedly experienced the epidemi/pandemi of infectious and fatal diseases, and the recent pandemi will not be the last of them. Therefore, investing in strengthening the scientific and practical infrastructure of our universities and pharmaceutical companies, will bring about lower costs for our country through the similar health crises that will unavoidably happen in the future.

Keywords

20.1001.1.2008935.1399.10.2.2.0

References

[1]. Jia, H. P., Look, D. C., Shi, L., Hickey, M., Pewe, L., Netland, J., Farzan, M., Wohlford-Lenane, C., Perlman, S., McCray, P. B. (2005). ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. Journal of virology, 79(23), 14614-14621.
[۲]. موسوی موحدی، فائزه، یوسفی، رضا (۱۳۹۸) ، ویروس کرونای جدید: از پیشگیری درمان تا سازوکار تکثیر و گسترش در بدن انسان، نشریه نشا علم، مجلد ۱۰، شماره ۱، صفحات ۵۳-۴۲.
[3]. Knisely JM, Liu B, Ranallo RT, Zou L., (2016). Vaccines for Healthcare-associated Infections: Promise and Challenge. Clinical Infectious Diseases, 63, 5: 657–662.
[4]. Bande, F., Arshad, S. S., Hair Bejo, M., Moeini, H., & Omar, A. R. (2015). Progress and challenges toward the development of vaccines against avian infectious bronchitis. Journal of immunology research, 2015.
[5]. Vidal, J. M., Kawabata, T. T., Thorpe, R., Silva-Lima, B., Cederbrant, K., Poole, S., Mueller-Berghaus, J., Pallardy, M., der Laan Van, J. W., (2010). In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine, 51(2), 213-215.
[6]. Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., ... & Larson, N. (2016). Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature, 531(7594), 381-385.
[7]. Agostini, M. L., Andres, E. L., Sims, A. C., Graham, R. L., Sheahan, T. P., Lu, X., ... & Ray, A. S. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio, 9(2), e00221-18.
[8]. Blaising, J., Polyak, S. J., & Pécheur, E. I. (2014). Arbidol as a broad-spectrum antiviral: an update. Antiviral research, 107, 84-94.
[9]. Aygen, B., Demirtürk, N., Yıldız, O., Çelik, İ., Güzel, D. K., Ersöz, G., ... & Tuna, N., (2019). Therapy in Hepatitis C Virus Infected Patients with Genotype 4 in Real-life Practice: A Multicentre Experience. Infect Dis Clin Microbiol, 1(2): 97-106.
[10]. Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019). Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses, 11(4), 326.
[11]. Westover, J. B., Mathis, A., Taylor, R., Wandersee, L., Bailey, K. W., Sefing, E. J., ... & Gowen, B. B. (2018). Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral research, 156, 38-45.
[12]. Gao, J., Tian, Z., & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. https://doi.org/10.5582/bst.2020.01047
[13]. Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., ...& Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery, 6(1), 1-4.
[14]. Kmietowicz, Z. (2017). WHO downgrades oseltamivir on drugs list after reviewing evidence? BMJ: British Medical Journal (Online), 357. DOI:10.1136/bmj. j2841
[15]. Kiselev, O. I., Deeva, E. G., Mel'nikova, T. I., Kozeletskaia, K. N., Kiselev, A. S., Rusinov, V. L., ... & Chupakhin, O. N. (2012). A new antiviral drug triazavirin: results of phase II clinical trial. Voprosy virusologii, 57(6), 9-12.
[16]. Stellbrink, H. J., Arastéh, K., Schürmann, D., Stephan, C., Dierynck, I., Smyej, I., ... & Mariën, K. (2014). Antiviral Activity, Pharmacokinetics, and Safety of the HIV-1 Protease Inhibitor TMC310911, Coadministered With Ritonavir, in Treatment-Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes, 65(3), 283-289.
[17]. Gupta, S., & Senapati, S. (2019). Mechanism of inhibition of drug-resistant HIV-1 protease clinical isolates by TMC310911: A molecular dynamics study. Journal of Molecular Structure, 1198, 126893.
[18]. Redeploying plant defenses. Nature Plants. 2020, 6:177. doi: 10.1038/s41477-020-0628-0.
[19]. Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., ...& Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell discovery, 6(1), 1-4.
[20]. Zakaryan, H., Arabyan, E., Oo, A., & Zandi, K. (2017). Flavonoids: promising natural compounds against viral infections. Archives of virology, 162(9), 2539-2551.
[21]. Orleans, L. A., is Vice, H., & Manchikanti, L. (2020). Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Pain Physician, 23, E71-E83
[22]. Metcalfe, S. M. (2020). Mesenchymal stem cells and management of COVID-19 pneumonia. Medicine in Drug Discovery,100019.https://doi.org/
10.1016/j.medidd.2020.100019.
[23]. Zheng, J., Yamada, Y., Fung, T. S., Huang, M., Chia, R., & Liu, D. X. (2018). Identification of N-linked glycosylation sites in the spike protein and their functional impact on the replication and infectivity of coronavirus infectious bronchitis virus in cell culture. Virology, 513, 65-74.
[24]. Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., ... & Müller, M. A. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell.